[go: up one dir, main page]

MX2022007725A - Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. - Google Patents

Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.

Info

Publication number
MX2022007725A
MX2022007725A MX2022007725A MX2022007725A MX2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A MX 2022007725 A MX2022007725 A MX 2022007725A
Authority
MX
Mexico
Prior art keywords
sub
cognitive impairment
compositions
containing gaba
treating
Prior art date
Application number
MX2022007725A
Other languages
English (en)
Inventor
Belew Mekonnen
John A Butera
Jianxing Huang
Robert Jason Herr
Qin Jiang
Emily Elizabeth Freeman
Hemantbhai Patel
Nicholas James Mayhew
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of MX2022007725A publication Critical patent/MX2022007725A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta invención se refiere a derivados de benzodiazepinas, composiciones que comprenden cantidades terapéuticamente efectivas de esos derivados y métodos para usar esos derivados o composiciones en el tratamiento de deterioro cognitivo asociado con trastornos del CNS. También se refiere al uso de un agonista del receptor de GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo para el receptor de GABAA que contiene a5) para tratar el deterioro cognitivo asociado con trastornos del CNS en un sujeto en necesidad o en riesgo de padecerlo, que incluye deterioro cognitivo relacionado con la edad, deterioro cognitivo leve (MCI), MCI amnésico, deterioro de la memoria asociado con la edad, disminución cognitiva relacionada con la edad, demencia, enfermedad de Alzheimer (AD), AD prodrómico, PTSD , esquizofrenia, trastorno bipolar, ALS, deterioro cognitivo relacionado con la terapia del cáncer, retraso mental, enfermedad de Parkinson, trastornos del espectro autista, trastorno X frágil, síndrome de Rett, comportamiento compulsivo y adicción a sustancias. También se refiere al uso de un agonista del receptor de GABAA que contiene a5 (por ejemplo, un modulador alostérico positivo del receptor de GABAA que contiene a5) en el tratamiento de cánceres cerebrales (que incluyen tumores cerebrales, por ejemplo, meduloblastomas) y deterioro cognitivo asociado con estos.
MX2022007725A 2019-12-19 2020-12-18 Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo. MX2022007725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950886P 2019-12-19 2019-12-19
PCT/US2020/066182 WO2021127543A1 (en) 2019-12-19 2020-12-18 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (1)

Publication Number Publication Date
MX2022007725A true MX2022007725A (es) 2022-07-19

Family

ID=76478828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007725A MX2022007725A (es) 2019-12-19 2020-12-18 Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.

Country Status (8)

Country Link
US (1) US20230098667A1 (es)
EP (1) EP4077333A4 (es)
JP (2) JP7737721B2 (es)
CN (1) CN115175911A (es)
AU (1) AU2020405233A1 (es)
IL (1) IL294031A (es)
MX (1) MX2022007725A (es)
WO (1) WO2021127543A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12039851B2 (en) * 2019-05-23 2024-07-16 Lifeguard Ai, Inc. System and a method for surveilling swimmers
EP4561444A1 (en) 2022-07-29 2025-06-04 F. Hoffmann-La Roche AG Characterisation of neurological dysfunction
WO2024039886A1 (en) * 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381561B (es) * 2013-12-20 2025-03-12 Agenebio Inc Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
US10815242B2 (en) * 2015-06-19 2020-10-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3104478A1 (en) * 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2021304356A1 (en) * 2020-07-10 2023-02-23 Agenebio, Inc. Combinations of GABAA ALPHA 5 agonists and SV2A inhibitors and methods of using in the treatment of cognitive impairment
IL299761A (en) * 2020-07-10 2023-03-01 Agenebio Inc GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment

Also Published As

Publication number Publication date
JP2023507569A (ja) 2023-02-24
IL294031A (en) 2022-08-01
AU2020405233A1 (en) 2022-07-14
US20230098667A1 (en) 2023-03-30
EP4077333A4 (en) 2024-01-10
JP7737721B2 (ja) 2025-09-11
WO2021127543A1 (en) 2021-06-24
EP4077333A1 (en) 2022-10-26
JP2025107315A (ja) 2025-07-17
CN115175911A (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
MX2020013927A (es) Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
MX388726B (es) Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
MX2022007725A (es) Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
MX381561B (es) Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo.
MX2020013374A (es) Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
MX376257B (es) Moduladores alostericos de receptores de acetilcolina nicotinicos.
AU2019268069A1 (en) Methods and compositions for improving cognitive function
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
MX346185B (es) Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
MX2023000405A (es) Combinaciones de agonistas del receptor a del acido gamma aminobutirico (gabaa) alfa 5 e inhibidores de la glicoproteina de vesicula sinaptica 2a (sv2a) y metodos de uso en el tratamiento del deterioro cognitivo.
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
EA202092608A1 (ru) Спиропиперидиновые аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
MX2025001992A (es) Derivados de benzazepina, composiciones y métodos para tratar deterioro cognitivo
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
Fujioka et al. Clinical presentation of a patient with SLC20A2 and THAP1 deletions: differential diagnosis of oromandibular dystonia
EA201691290A1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения
NZ776101B2 (en) Extended release pharmaceutical compositions of levetiracetam
NZ776101A (en) Extended release pharmaceutical compositions of levetiracetam
NZ755287B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
PH12019550251A1 (en) HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
EA201892113A1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
NZ739092B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment